Therefore, blockage of CTLA-4 on lymphocytes might allow for overriding adverse suppression of the anti-tumor immune response through reduction of cells bearing suppressive potential, including IL-10-producing Th2 cells, or possibly even Foxp3+ regulatory T cells or IL-10-producing regulatory B cells. Here, CTLA4 is linked to neoplasm.